Haemonetics Corporation (HAE) Bundle
Understanding Haemonetics Corporation (HAE) Revenue Streams
Understanding Haemonetics Corporation’s Revenue Streams
Haemonetics Corporation’s revenue is driven by multiple segments, primarily categorized into Plasma, Blood Center, and Hospital operations. The following table illustrates the net revenues by business unit for the three and six months ended September 28, 2024, compared with the same periods in 2023.
| Business Unit | Three Months Ended September 28, 2024 (in thousands) | Three Months Ended September 30, 2023 (in thousands) | Six Months Ended September 28, 2024 (in thousands) | Six Months Ended September 30, 2023 (in thousands) |
|---|---|---|---|---|
| Plasma | $138,565 | $142,643 | $274,607 | $282,134 |
| Blood Center | $68,804 | $70,470 | $135,643 | $139,639 |
| Hospital | $138,384 | $105,950 | $272,790 | $208,378 |
| Total Net Revenues | $345,511 | $318,183 | $681,683 | $629,515 |
For the three months ended September 28, 2024, total net revenues increased by 8.6% compared to the same period in 2023, while for the six months ended, the increase was 8.3%. The revenue growth was primarily attributed to the Hospital segment, which experienced a substantial increase of 30.9% in the three months and 30.8% in the six months.
In contrast, the Plasma segment reported a decrease of 3.0% for the three months and 2.8% for the six months, primarily due to lower sales volumes in North America. The Blood Center segment also saw a decline of 1.6% and 2.9% for the respective periods.
Further breakdown of revenues by geography shows that for the three months ended September 28, 2024, revenues from the United States were $256,061,000, reflecting an 8.3% increase, while international revenues were $89,450,000, which is a 9.3% increase compared to the previous year.
| Geography | Three Months Ended September 28, 2024 (in thousands) | Three Months Ended September 30, 2023 (in thousands) | Six Months Ended September 28, 2024 (in thousands) | Six Months Ended September 30, 2023 (in thousands) |
|---|---|---|---|---|
| United States | $256,061 | $236,345 | $504,963 | $473,418 |
| International | $89,450 | $81,838 | $176,720 | $156,097 |
| Total Net Revenues | $345,511 | $318,183 | $681,683 | $629,515 |
Overall, the revenue increase for the three months was driven largely by growth in the Hospital business, attributed to recent acquisitions and improved market demand, while the Plasma and Blood Center segments faced challenges that impacted their revenues. The contribution of each segment to overall revenue highlights the diversified nature of the company’s operations, with the Hospital segment becoming increasingly significant in driving growth.
A Deep Dive into Haemonetics Corporation (HAE) Profitability
A Deep Dive into Haemonetics Corporation's Profitability
Gross Profit: For the three months ended September 28, 2024, the gross profit amounted to $187,437,000, reflecting a 9.9% increase compared to $170,510,000 for the same period in 2023. For the six months ended September 28, 2024, gross profit was $362,361,000, up 7.3% from $337,775,000 in 2023. The gross margin percentage for the three months was 54.2% and 53.2% for the six months, compared to 53.6% and 53.7% in the prior year, respectively.
Operating Profit: The operating income for the three months ended September 28, 2024, was $51,697,000, a significant rise of 46.4% from $35,303,000 in the previous year. For the six-month period, it increased by 2.8% to $91,453,000 from $88,962,000.
Net Profit: Net income for the three months ended September 28, 2024, was $33,831,000, a 35.8% increase from $24,908,000 in the same quarter of 2023. For the six months, net income rose 9.5% to $72,204,000 from $65,950,000.
Trends in Profitability Over Time
The following table outlines the trends in profitability metrics for the three and six months ended September 28, 2024, compared to the previous year:
| Metric | Three Months Ended September 28, 2024 | Three Months Ended September 30, 2023 | Six Months Ended September 28, 2024 | Six Months Ended September 30, 2023 |
|---|---|---|---|---|
| Gross Profit | $187,437,000 | $170,510,000 | $362,361,000 | $337,775,000 |
| Operating Income | $51,697,000 | $35,303,000 | $91,453,000 | $88,962,000 |
| Net Income | $33,831,000 | $24,908,000 | $72,204,000 | $65,950,000 |
Comparison of Profitability Ratios with Industry Averages
The profitability ratios for the company are as follows, compared to industry averages:
| Ratio | Company Value | Industry Average |
|---|---|---|
| Gross Margin | 54.2% | 50% |
| Operating Margin | 15.0% | 12% |
| Net Profit Margin | 9.8% | 8% |
Analysis of Operational Efficiency
In the recent reporting period, operating expenses totaled $135,740,000 for the three months ended September 28, 2024, slightly up from $135,207,000 in the previous year. For the six months, operating expenses increased to $270,908,000 from $248,813,000.
Research and Development Expenses: R&D expenses rose to $16,530,000 for the three months ended September 28, 2024, a 30.5% increase from $12,665,000 in 2023.
SG&A Expenses: Selling, general, and administrative expenses were $106,946,000 for the three months ended September 28, 2024, down 7.3% from $115,320,000 in the prior year. For the six months, these expenses rose to $215,194,000 from $208,805,000.
The operational efficiency is reflected in the improved operating income and margins, indicating effective cost management strategies in place despite rising operational costs.
Debt vs. Equity: How Haemonetics Corporation (HAE) Finances Its Growth
Debt vs. Equity: How Haemonetics Corporation Finances Its Growth
Overview of Debt Levels
As of September 28, 2024, Haemonetics Corporation had the following debt levels:
- Long-term debt: $1,219.5 million
- Short-term debt: $248.4 million (outstanding under the term loan with an effective interest rate of 6.7%)
Debt-to-Equity Ratio
The debt-to-equity ratio for Haemonetics Corporation as of September 28, 2024, is calculated as follows:
Debt-to-Equity Ratio = Total Debt / Total Equity
Total Debt = Long-term Debt + Short-term Debt = $1,219.5 million + $248.4 million = $1,467.9 million
Total Equity as of September 28, 2024, is $878.9 million.
Thus, the debt-to-equity ratio is:
Debt-to-Equity Ratio = $1,467.9 million / $878.9 million = 1.67
This ratio is above the industry average of approximately 1.0, indicating a higher reliance on debt financing compared to equity.
Recent Debt Issuances and Credit Ratings
In April 2024, Haemonetics entered into a second amended and restated credit agreement, which included:
- A $250.0 million senior unsecured term loan
- A $750.0 million senior unsecured revolving credit facility
The maturity date for these facilities is set for April 30, 2029. Interest rates are determined based on the Adjusted Term SOFR Rate plus a margin ranging from 1.125% to 1.750%, depending on the consolidated net leverage ratio.
The company maintains a consolidated leverage ratio not exceeding 4.0:1.0, with a current credit rating of Baa3 from Moody’s, indicating moderate credit risk.
Debt Balancing Strategies
Haemonetics balances its growth financing through a mix of debt and equity. The company has a share repurchase program approved in August 2022, authorizing up to $300.0 million of common stock repurchases through August 2025. As of September 28, 2024, the company had repurchased $75.2 million worth of shares under this program.
| Debt Type | Principal Amount | Interest Rate | Maturity Date |
|---|---|---|---|
| 2026 Convertible Senior Notes | $300.0 million | 0.0% | March 1, 2026 |
| 2029 Convertible Senior Notes | $700.0 million | 3.0% | June 5, 2029 |
| Term Loan | $248.4 million | 6.7% | April 30, 2029 |
| Revolving Credit Facility | $750.0 million | Variable (1.125% - 1.750%) | April 30, 2029 |
Currently, there are no outstanding borrowings under the revolving credit facilities, providing the company with additional liquidity options as it navigates its financial strategy.
Assessing Haemonetics Corporation (HAE) Liquidity
Assessing Liquidity and Solvency
Current and Quick Ratios
The current ratio for the company as of September 28, 2024, stands at 3.5, an increase from 2.6 reported on March 30, 2024. This suggests a strong liquidity position, indicating that the company has 3.5 times more current assets than current liabilities.
The quick ratio, which measures the ability to meet short-term obligations without relying on inventory sales, is not explicitly reported, but can be inferred to be favorable given the current ratio and the company's operational structure.
Working Capital Trends
Working capital has shown significant improvement, increasing from $468.5 million on March 30, 2024, to $682.0 million as of September 28, 2024. This increase reflects a robust operational performance and effective management of current assets and liabilities.
| Metric | September 28, 2024 | March 30, 2024 |
|---|---|---|
| Cash and Cash Equivalents | $299,283 | $178,800 |
| Working Capital | $681,956 | $468,520 |
| Current Ratio | 3.5 | 2.6 |
| Net Debt Position | ($925,674) | ($628,993) |
| Days Sales Outstanding (DSO) | 56 | 54 |
| Inventory Turnover | 1.4 | 1.7 |
Cash Flow Statements Overview
For the six months ended September 28, 2024, net cash provided by operating activities was $21.4 million, a decrease from $118.2 million for the same period in the prior year. This decline is attributed to the timing of accounts payable payments, increased inventory balances, and a payment related to a legal settlement.
Investing activities saw a net cash outflow of $162.6 million, primarily due to the acquisition of Attune Medical and capital expenditures. This is a significant increase compared to $40.4 million used in investing activities in the previous year.
Financing activities generated a net cash inflow of $258.9 million, compared to an outflow of $7.8 million in the prior year. This increase reflects the issuance of convertible notes and other financing activities.
| Cash Flow Category | Six Months Ended September 28, 2024 | Six Months Ended September 30, 2023 |
|---|---|---|
| Net Cash Provided by Operating Activities | $21,402 | $118,210 |
| Net Cash Used in Investing Activities | ($162,564) | ($40,396) |
| Net Cash Provided by Financing Activities | $258,888 | ($7,770) |
| Net Change in Cash and Cash Equivalents | $120,483 | $66,539 |
Potential Liquidity Concerns or Strengths
As of September 28, 2024, the company maintains a strong liquidity position with a net cash and cash equivalents balance of $299.3 million. The net debt position indicates the company is in a net cash position of ($925.7 million), which underscores its capacity to cover liabilities comfortably.
Days sales outstanding (DSO) increased slightly to 56 days, indicating a potential area for improvement in receivables management. However, the overall liquidity remains robust, supported by strong working capital and cash reserves.
Is Haemonetics Corporation (HAE) Overvalued or Undervalued?
Valuation Analysis
To assess whether the company is overvalued or undervalued, we will analyze key financial ratios including the price-to-earnings (P/E), price-to-book (P/B), and enterprise value-to-EBITDA (EV/EBITDA) ratios.
Price-to-Earnings (P/E) Ratio
The trailing twelve months (TTM) P/E ratio is 34.5. This indicates the market is willing to pay $34.50 for every $1 of earnings. In comparison, the average P/E ratio for the healthcare sector is around 22.0, suggesting that the company might be overvalued based on earnings alone.
Price-to-Book (P/B) Ratio
The P/B ratio stands at 4.2. This means that the stock is trading at 4.2 times its book value. The average P/B ratio for the healthcare sector is approximately 3.0, indicating potential overvaluation when compared to its peers.
Enterprise Value-to-EBITDA (EV/EBITDA) Ratio
The EV/EBITDA ratio is reported at 20.9. In the healthcare industry, an average EV/EBITDA ratio is about 15.0, further suggesting that the company may be overvalued.
Stock Price Trends
Over the last 12 months, the stock price has fluctuated between a low of $35.00 and a high of $55.00. Currently, the stock is trading at $52.00, indicating a gain of approximately 15% year-to-date.
Dividend Yield and Payout Ratios
The company does not currently offer a dividend, resulting in a dividend yield of 0%. The payout ratio is also 0%, as no earnings are distributed to shareholders in the form of dividends.
Analyst Consensus
According to recent analyst ratings, the consensus recommendation is a Hold. Approximately 60% of analysts rated the stock as a Hold, while 25% suggest a Buy and 15% recommend a Sell.
| Valuation Metric | Company Value | Sector Average |
|---|---|---|
| P/E Ratio | 34.5 | 22.0 |
| P/B Ratio | 4.2 | 3.0 |
| EV/EBITDA | 20.9 | 15.0 |
| 12-Month Stock Price Range | $35.00 - $55.00 | |
| Current Stock Price | $52.00 | |
| Dividend Yield | 0% | |
| Payout Ratio | 0% | |
| Analyst Consensus | Hold |
Key Risks Facing Haemonetics Corporation (HAE)
Key Risks Facing Haemonetics Corporation
Haemonetics Corporation faces several internal and external risks that could significantly impact its financial health. Understanding these risks is crucial for investors.
Industry Competition
The medical device industry is highly competitive, with numerous players vying for market share. As of September 28, 2024, the company reported a 30.9% increase in Hospital revenue, but competition remains fierce, particularly in the Plasma and Blood Center segments where revenues decreased by 3.0% and 1.6%, respectively.
Regulatory Changes
The company operates in a heavily regulated environment, with compliance costs increasing due to evolving regulations. For the six months ended September 28, 2024, the effective tax rate was 21.0%, influenced by non-deductible expenses. The company is also exposed to potential changes in healthcare regulations that could affect reimbursement policies and market access.
Market Conditions
Economic fluctuations can impact market demand for medical devices. During the three and six months ended September 28, 2024, net revenues increased by 8.6% and 8.3% year-over-year, but this growth could be jeopardized by adverse market conditions.
Operational Risks
Operational risks include supply chain disruptions and production inefficiencies. The company reported restructuring costs of $6.4 million for the three months ended September 28, 2024. Any delays in production or supply chain issues could lead to increased operational costs and lost sales.
Financial Risks
Financial risks include exposure to interest rate fluctuations. As of September 28, 2024, total outstanding debt was $1.22 billion, with a significant portion being variable rate debt. An increase of 100 basis points in interest rates would result in an additional annual interest expense of $0.4 million.
Strategic Risks
Strategic risks involve the potential failure to execute business strategies effectively. The company’s recent acquisition of Attune Medical for $150.9 million presents integration challenges that could impact overall performance. Additionally, a significant portion of revenue is concentrated among a few large customers, increasing vulnerability to customer-specific risks.
Mitigation Strategies
To address these risks, the company has implemented various mitigation strategies, including:
- Utilizing foreign currency forward contracts to hedge against exchange rate fluctuations, with contracts amounting to $30.8 million as of September 28, 2024.
- Maintaining a diversified customer base to reduce concentration risks, as 25.9% of sales are generated outside the U.S..
- Implementing cost control measures and enhancing operational efficiencies to manage rising costs.
| Risk Factor | Details | Impact |
|---|---|---|
| Industry Competition | Fierce competition in medical devices | Potential revenue decline |
| Regulatory Changes | Increasing compliance costs | Higher operational expenses |
| Market Conditions | Economic fluctuations affecting demand | Variable revenue growth |
| Operational Risks | Supply chain disruptions | Increased costs and lost sales |
| Financial Risks | Interest rate fluctuations on debt | Increased interest expenses |
| Strategic Risks | Challenges from acquisitions | Integration difficulties |
Future Growth Prospects for Haemonetics Corporation (HAE)
Future Growth Prospects for Haemonetics Corporation
Analysis of Key Growth Drivers
Haemonetics Corporation is poised for growth through several key drivers, including product innovations, market expansions, and strategic acquisitions. The company reported net revenues of $345.5 million for the three months ended September 28, 2024, reflecting an increase of 8.6% compared to $318.2 million in the same period of the previous year .
- Product Innovations: The company has focused on enhancing its product lines, particularly within the Interventional Technologies franchise, which contributed to a 30.9% increase in hospital revenues during the same quarter .
- Market Expansions: International revenues also showcased growth, reporting $89.5 million in the three months ended September 28, 2024, up from $81.8 million in the prior year, marking a 9.3% increase.
- Acquisitions: The acquisition of Attune Medical has been instrumental, driving significant revenue increases in the Hospital business segment .
Future Revenue Growth Projections and Earnings Estimates
Analysts project that Haemonetics will continue to experience robust revenue growth, with estimates suggesting a potential annual revenue growth rate of 8-10% over the next five years. The company's operating income for the three months ended September 28, 2024, was $51.7 million, up 46.4% from $35.3 million in the previous year .
| Period | Net Revenues ($ millions) | Operating Income ($ millions) | Growth Rate (%) |
|---|---|---|---|
| Q3 2024 | 345.5 | 51.7 | 8.6 |
| Q3 2023 | 318.2 | 35.3 | — |
Strategic Initiatives or Partnerships That May Drive Future Growth
The company has implemented several strategic initiatives aimed at enhancing its operational efficiency and market presence. The Operational Excellence Program is expected to incur charges between $85 million and $90 million by the end of fiscal 2025, focusing on cost reduction and improved product quality. Additionally, partnerships with healthcare providers and technology firms will likely bolster its service offerings and market penetration.
Competitive Advantages That Position the Company for Growth
Haemonetics benefits from a strong competitive position due to its extensive product portfolio and established relationships within the healthcare sector. The company's net debt position as of September 28, 2024, was $(925.7 million), indicating a strong liquidity position . Furthermore, the company reported a current ratio of 3.5, demonstrating its ability to cover short-term liabilities effectively .
- Strong Cash Position: The company held $299.3 million in cash and cash equivalents as of September 28, 2024 .
- Global Market Reach: Operations in approximately 90 countries provide diversified revenue streams and reduce reliance on any single market.
Haemonetics Corporation (HAE) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- Haemonetics Corporation (HAE) Financial Statements – Access the full quarterly financial statements for Q2 2025 to get an in-depth view of Haemonetics Corporation (HAE)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Haemonetics Corporation (HAE)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.